Chronic hepatitis C in the state prison system: insights into the problems and possible solutions

References

• Grant WC, Jhaveri RR, McHutchison JG, Schulman KA, Kauf TL. Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology42(6), 1406–1413 (2005).
   PubMed Web of Science ®Google Scholar
• Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology127(5 Suppl. 1), S35–S50 (2004).
   PubMed Web of Science ®Google Scholar
• Wong JB, McQuillanGM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am. J. Public Health90(10), 1562–1569 (2000).
   PubMed Web of Science ®Google Scholar
• Macalino GE, Vlahov D, Dickinson BP, Schwartzapfel B, Rich JD. Community incidence of hepatitis B and C among reincarcerated women. Clin. Infect. Dis.41(7), 998–1002 (2005).
   PubMed Web of Science ®Google Scholar
• Kerr T. Reconsidering the public health failings of the criminal justice system: a reflection on the case of Scott Ortiz. Harm Reduct. J.25(3), 1–2 (2006).
   Google Scholar
• Sagir A, Heintges T, Akyazi Z, Oette M, Erhardt A, Häussinger D. Therapy outcome in patients with chronic hepatitis C: role of therapy supervision by expert hepatologists. J. Viral Hepat.14(9), 633–638 (2007).
   PubMed Web of Science ®Google Scholar
• Weinbaum C, Lyerla R, Margolis HS. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Recomm. Rep.52(RR-1), 1–36 (2003).
   PubMedGoogle Scholar
• Rieger D. Universal HCV testing in Indiana-pros and cons. Presented at: Consultation of the Management of Hepatitis C in Prisons. San Antonio, TX, USA, 25–26 January 2003.
   Google Scholar
• Ruiz JD, Molitor F, Sun RK et al. Prevalence and correlates of hepatitis C virus infection among inmates entering the California correctional system. West J. Med.170(3), 156–160 (1999).
   PubMedGoogle Scholar
• Fox RK, Currie SL, Evans J et al. Hepatitis C virus infection among prisoners in the California state correctional system. Clin. Infect. Dis.41(2), 177–186 (2005).
   PubMed Web of Science ®Google Scholar
• Harzke AJ, Baillargeon J, Paar DP, Pulvino J, Murray OJ. Chronic liver disease mortality among male prison inmates in Texas, 1989–2003. Am. J. Gastroenterol.104(6), 1412–1419 (2009).
   PubMed Web of Science ®Google Scholar
• Spaulding AC, Weinbaum CM, Lau DT et al. A framework for management of hepatitis C in prisons. Ann. Intern. Med.144(10), 762–769 (2006).
   PubMed Web of Science ®Google Scholar
• Harzke AJ, Baillargeon JG, Kelley MF, Diamond PM, Goodman KJ, Paar DP. HCV-related mortality among male prison inmates in Texas, 1994–2003. Ann. Epidemiol.19(8), 582–589 (2009).
   PubMed Web of Science ®Google Scholar
• Tan A, Tom J, Saab S. Treating hepatitis C in the prison population is cost-saving. Hepatology48(5), 1387–1395 (2008).
   PubMed Web of Science ®Google Scholar
• Klein SJ, Wright LN, Birkhead GS. Promoting HCV treatment completion for prison inmates: New York State’s hepatitis C continuity program. Public Health Rep.122(Suppl. 2), 83–88 (2007).
   PubMed Web of Science ®Google Scholar
• Singal AK, Singh A, Jaganmohan S et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-induced cirrhosis. Clin. Gastroenterol. Hepatol.8, 192–199 (2010).
   PubMed Web of Science ®Google Scholar
• Bruno S, Stroffolini T, Colombo M et al. Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology45(3), 579–587 (2007).
   PubMed Web of Science ®Google Scholar
• Mahoney M, McPhee. Barriers to HCV treatment in a women’s facility. Presented at: 2nd Annual Academic and Health Policy Conference on Correctional Health. Quincy, MA, USA, 27 March 2008.
   Google Scholar
• Rossaro L, Aoki C, Yuk J, Prosser C, Goforth J, Martinez F. The evaluation of patients with hepatitis C living in rural California via telemedicine. Telemed. J. E Health.14(10), 1127–1129 (2008).
   PubMed Web of Science ®Google Scholar
• Arora S, Thornton K, Jenkusky SM, Parish B, Scaletti JV. Project ECHO: linking university specialists with rural and prison-based clinicians to improve care for people with chronic hepatitis C in New Mexico. Public Health Rep.122(Suppl. 2), 74–77 (2007).
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology49(4), 1335–1374 (2009).
   PubMed Web of Science ®Google Scholar
• Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann. Intern. Med.138(3), 187–190 (2003).
   PubMed Web of Science ®Google Scholar
• Sterling RK, Brown RS Jr, Hofmann CM. The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV. Am. J. Gastroenterol.100(2), 313–321 (2005).
   PubMed Web of Science ®Google Scholar
• Sabbatani S, Giuliani R, Manfredi R. Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting. Braz. J. Infect. Dis.10(4), 274–278 (2006).
   PubMedGoogle Scholar
• Afdhal N, McHutchison J, Brown R et al. Thrombocytopenia associated with chronic liver disease. J. Hepatol.48(6), 1000–1007 (2008).
   PubMed Web of Science ®Google Scholar
• Seeff LB. Natural History of Chronic Hepatitis C. Hepatology36(Suppl. 5), S35–S46 (2002).
   PubMed Web of Science ®Google Scholar
• Nachin P, Kerbleski M, Gaglioti et al. Use of telemedicine and the “warm line” for the treatment of hepatitis c infection (HCV) in the correctional setting to reduce barriers to specialty care. Hepatology.50(Suppl. 4), 660A (2009).
   PubMed Web of Science ®Google Scholar
• Hunt DR, Saab S. Viral hepatitis in incarcerated adults: a medical and public health concern. Am. J. Gastroenterol.104(4), 1024–1031 (2009).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 Infection. N. Engl. J. Med.360(18), 1827–1838 (2009).
   PubMed Web of Science ®Google Scholar